. Cristallise, On filtre le précipité que l'on lave au cyclohexane et à l'éther. On obtient un solide beige avec un rendement de 76%

. Le-produit-32a, 1 g, 1 eq) est mis en solution dans 13 ml de BuOH. A cette solution on rajoute la benzylamine (4.45 mmol, 0.6 ml, 1.2 eq) et la Et 3 N (18.5 mmol, 2.6 ml, 5 eq) Après chauffage à reflux pendant 20 h, un solide se forme. Ce dernier est filtré, lavé avec 1 ml de BuOH froid et séché à l'étuve. La réaction est suivie par plaque CCM (DCM/ Cyc, On obtient un solide jaune clair avec un Rdt 97%

. Dans-un-bain-de-glace, on dissout le produit 33d (3.28 mmol, 1.2 g, 1 eq) dans 65 ml de dichlorométhane, puis on additionne 0,88 g (1.5 eq) d'acide meta-chloroperbenzoïque a 80%

. Dans-un-bain-de-glace, on dissout le produit 33e (3.8 mmol, 1g, 1 eq) dans 65 ml de dichlorométhane, puis on additionne 0,78 g (1.5 eq) d'acide meta-chloroperbenzoïque a 80%

. Dans-un-tube-fermé, le produit 38d (1 mmol, 0.4 g, 1 eq) est mis en réaction avec du Raminobutanol (8 mmol, 0.75 ml, 8 eq) en chauffant à 100°C pendant 24 h. Après extraction par DCM et évaporation sous vide

C. La-réaction-est-suivie-par and . Acoet, On obtient une poudre crème avec un Rdt de 35%, pp.89-95

. Dans-un-tube-fermé, mmol, 0.4 g, 1 eq) est mis en réaction avec du 2- aminopropane-1,3-diol (5 mmol, 0.6g, 5 eq) en chauffant à 100°C pendant 12 h. après extraction par AcOEt et évaporation sous vide, le produit formé cristallisé dans l'éther, pp.38-85

-. Nh-chm, 5. , 1. , and N. , (ppm): 3.50 (s, 4H, 2 CH 2 OH), 3.92 (s, 1H, pp.64-67

. Dans-un-tube-fermé, 5 mmol, 0.5 g, 1 eq) est mis en réaction avec du Raminobutanol (7.5 mmol, 0.67 ml, 5 eq) en chauffant à 100°C pendant 48 h. Après extraction par DCM, on purifie le brut sur une colonne (DCM/ AcOEt, puis on évapore sous vide, le produit formé cristallise dans l'éther, p.38

C. La-réaction-est-suivie-par and . Acoet, On obtient une poudre crème avec un Rdt de 35%, pp.110-110

3. , 1. Nhch-)-s, and 1. Oh-)-6h, 72-3.78 (m, 2H, CH 2 OH), pp.55-58

L. Meijer and E. Raymond, Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials, Accounts of Chemical Research, vol.36, issue.6, pp.417-442, 2003.
DOI : 10.1021/ar0201198

URL : https://hal.archives-ouvertes.fr/hal-00020144

R. H. Niedner, O. Buzko, and N. Haste, Protein kinase resource: An integrated environment for phosphorylation research, Proteins: Structure, Function, and Bioinformatics, vol.1, issue.5, pp.78-86, 2006.
DOI : 10.1002/prot.20825

A. Borgne and L. Meijer, The search for and potential therapeutic applications of chemical inhibitors of cyclin-dependent kinases, Med. Sci, vol.15, pp.496-503, 1999.

R. Przewlocki, Effects of glycogen synthase kinase 3 beta and cyclin-dependent kinase 5

F. Superti, M. G. Ammendolia, and M. Marchetti, New Advances in Anti-HSV Chemotherapy, Current Medicinal Chemistry, vol.15, issue.9, pp.900-911, 2008.
DOI : 10.2174/092986708783955419

P. Diwan, J. J. Lacasse, and L. M. Schang, Roscovitine Inhibits Activation of Promoters in Herpes Simplex Virus Type 1 Genomes Independently of Promoter-Specific Factors, Journal of Virology, vol.78, issue.17, pp.9352-65, 2004.
DOI : 10.1128/JVI.78.17.9352-9365.2004

K. C. Bible, J. L. Lensing, S. A. Nelson, Y. K. Lee, J. M. Reid et al., Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points, Clinical Cancer Research, vol.11, issue.16, pp.5935-5976, 2005.
DOI : 10.1158/1078-0432.CCR-04-2566

A. Dey, E. T. Wong, C. F. Cheok, V. Tergaonkar, and D. P. Lane, R-Roscovitine simultaneously targets both the p53 and NF-??B pathways and causes potentiation of apoptosis: implications in cancer therapy, Cell Death and Differentiation, vol.19, issue.2, pp.263-73, 2008.
DOI : 10.1038/sj.onc.1207709

H. Galons, N. Oumata, O. Gloulou, and L. Meijer, Cyclin-dependent kinase inhibitors closer to market launch?, Expert Opinion on Therapeutic Patents, vol.29, issue.8, pp.945-63, 2013.
DOI : 10.4161/cbt.12.7.16475

R. Williams, Discontinued drugs in 2007: oncology drugs, Expert Opinion on Investigational Drugs, vol.1, issue.12, pp.1791-816, 2008.
DOI : 10.1038/nrd1470

L. R. Chirieac, J. H. Schellens, and G. I. Shapiro, Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours, Ann. Oncol, vol.21, pp.884-894, 2010.

L. Meijer, K. Bettayeb, H. Galons, E. Yue, and P. Smith, Roscovitine (CYC202, Seliciclib) CDK inhibitors and their potential as anti-tumor agents, monographs on enzyme inhibitors, pp.187-226, 2006.

H. Galons, N. Oumata, and L. Meijer, Cyclin-dependent kinase inhibitors : a survey of recent patent literature. Expert opin. Ther. Patents, pp.3-377, 2010.

J. G. Delcros and J. P. Moulinoux, Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2

D. P. Lane, M. Hubank, J. E. Powell, W. Wei, A. M. Taylor et al., A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in Cyclin- Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging 279 p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival, Blood, issue.11, pp.105-4484, 2005.

J. Karp, Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias, Blood, vol.117, issue.12, pp.3302-3312, 2011.
DOI : 10.1182/blood-2010-09-310862

D. Parry, T. Guzi, F. Shanahan, N. Davis, D. Prabhavalkar et al., ) a novel and potent cyclin-dependent kinase inhibitor, Mol. Cancer Ther, vol.2010, issue.8, pp.9-2344, 727965.

A. Conroy, D. E. Stockett, D. Walker, M. R. Arkin, U. Hoch et al., SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples, Cancer Chemotherapy and Pharmacology, vol.352, issue.Suppl 4, pp.723-755, 2009.
DOI : 10.1007/s00280-008-0921-5

W. G. Tong, R. Chen, W. Plunkett, D. Siegel, . R. Sinha et al., Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma, Phase I and pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor Patients with Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma, pp.3015-3037, 2010.
DOI : 10.1200/JCO.2009.26.1347

W. Plunkett, Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia, Blood, vol.113, pp.4637-4682, 2009.

E. Menu, J. Garcia, X. Huang, M. Di-liberto, P. L. Toogood et al., A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model, Cancer Research, vol.68, issue.14, pp.68-5519, 2008.
DOI : 10.1158/0008-5472.CAN-07-6404

J. Wesierska-gadek, M. Maurer, N. Zulehner, and O. Komina, Whether to target single or multiple CDKs for therapy? That is the question, Journal of Cellular Physiology, vol.9, issue.Pt 14, pp.341-350, 2011.
DOI : 10.1002/jcp.22426

E. F. Navarro, M. A. O-'brien, M. O-'reilly, M. Reule, G. Saxty et al., Identification of N-(4- piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragmentbased X-ray crystallography and structure based drug design, J. Med. Chem, issue.16, pp.51-4986, 2008.

D. Mahadevan, R. Plummer, M. S. Squires, D. Rensvold, S. Kurtin et al., A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors, Annals of Oncology, vol.22, issue.9, pp.2137-2180, 2011.
DOI : 10.1093/annonc/mdq734

M. Boccadoro, P. G. Richardson, N. C. Munshi, K. C. Anderson, and N. Raje, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition

D. Mahadevan, AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples, Mol. Cancer. Ther, vol.9, issue.4, pp.920-928, 2010.

M. S. Squires, R. E. Feltell, N. G. Wallis, E. J. Lewis, D. M. Smith et al., Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines, Molecular Cancer Therapeutics, vol.8, issue.2, pp.324-356, 2009.
DOI : 10.1158/1535-7163.MCT-08-0890

K. S. Joshi, M. J. Rathos, R. D. Joshi, M. Sivakumar, M. Mascarenhas et al., In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00, Molecular Cancer Therapeutics, vol.6, issue.3, pp.276-276, 2006.
DOI : 10.1158/1535-7163.MCT-06-0613

M. Sivakumar, A. Maier, H. H. Fiebig, and S. Sharma, P276-00, a novel cyclindependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatinresistant cells and significant in vivo efficacy in tumor models, Mol. Cancer. Ther, issue.3, pp.926-960, 2006.

K. Ziegelbauer, Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models, Proceedings of the 101 st Annual Meeting of the American Association for Cancer Research (AACR), Abstract number 3883, 2010.

D. Castiglia, C. Covaciu, E. Bonmassar, and S. Atri, The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound, Pharmacol. Res, issue.5, pp.61-437, 2010.

A. Galvani, A. Isacchi, J. Moll, E. Pesenti, C. Mercurio et al., Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy, Mol. Cancer. Ther, issue.8, pp.9-2243, 2010.

O. M. Tirado, S. Mateo-lozano, V. Notario, P. Colas, P. Bernard et al., Pyrazolo[1,5-a]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin- Dependent Kinase Inhibitor (R)-Roscovitine Analogue, J. Med. Chem, vol.52, pp.655-63, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00416036

F. I. Raynaud, S. R. Whittaker, P. M. Fischer, S. Mcclue, M. I. Walton et al., In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202, Clinical Cancer Research, vol.11, issue.13, pp.4875-87, 2005.
DOI : 10.1158/1078-0432.CCR-04-2264

S. Lapenna and A. Giordano, Cell cycle kinases as therapeutic targets for cancer, Nature Reviews Drug Discovery, vol.99, issue.3, pp.547-66, 2009.
DOI : 10.1038/nrd2907

R. N. Misra, J. T. Hunt, S. D. Kimball, W. G. Humphreys, B. S. Wautlet et al., Thio-and Oxoflavopiridols, Cyclin-Dependent Kinase1 Selective Inhibitors: Synthesis and Biological Effects, J. Med. Chem, vol.43, pp.4126-4160, 2000.

D. W. Fry, P. J. Harvey, P. R. Keller, W. L. Elliott, M. Meade et al., Specific inhibition of cyclindependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol. Cancer Ther, vol.3, pp.1427-1465, 2004.

M. Atefi, I. Chen, C. Fowst, G. Los, and D. J. Slamon, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro, Breast Cancer Res, issue.5, pp.11-77, 2009.

E. A. Musgrove, C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland, Cyclin D as a therapeutic target in cancer, Nature Reviews Cancer, vol.64, issue.8, pp.558-72, 2011.
DOI : 10.1038/nrc3090

E. O. Aboagye, R. C. Coombes, A. G. Barrett, and S. A. Ali, Novel Pyrazolo[1,5- a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration, J. med. Chem, issue.24, pp.53-8508, 2010.

. Pyrazolo, 3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity, J. Med. Chem, vol.4, issue.8, pp.54-2980, 2011.

V. M. Yenugonda, T. B. Deb, S. C. Grindrod, S. Dakshanamurthy, Y. Yang et al., Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells, Bioorganic & Medicinal Chemistry, vol.19, issue.8, pp.19-2714, 2011.
DOI : 10.1016/j.bmc.2011.02.052

P. Roussel, A. Vulpetti, and M. G. Brasca, Identification of Potent Pyrazolo[4,3- h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors, J. med

S. G. Ahn, J. H. Yoon, S. Y. Han, J. I. Kim, and Y. C. Kim, 5?-Substituted Indirubin-3?- oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity, J. med. chem, vol.5, issue.53, pp.3696-3706, 2010.

P. M. Fischer, Design, Synthesis, and Evaluation of 2-Methyl-and 2-Amino-N-aryl-4,5- dihydrothiazolo[4,5-h]quinazolin-8-amines as Ring-Constrained 2-Anilino-4-(thiazol-5- yl)pyrimidine Cyclin-Dependent Kinase Inhibitors, J. med. Chem, issue.5, pp.53-2136, 2010.

S. Ayral-kaloustian and T. S. Mansour, Discovery of 4-(Benzylaminomethylene)isoquinoline- 1,3-(2H,4H)-diones and 4-[(Pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)- diones as Potent and Selective Inhibitors of the Cyclin-Dependent Kinase 4, J. med

P. Orsini, W. Pastori, E. Pesenti, P. Pevarello, P. Roussel et al., Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing, Bioorg. Med. Chem, vol.18, pp.1844-53, 2010.

J. Lee, K. H. Kim, and S. Jeong, Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.21, issue.14, pp.4203-4208, 2011.
DOI : 10.1016/j.bmcl.2011.05.081

D. Wiswell and T. J. Guzi, Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 2, Bioorg. Med. Chem. Lett, vol.21, pp.471-74, 2011.

X. Liu, S. Shi, F. Lam, C. Pepper, P. M. Fischer et al., CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol, International Journal of Cancer, vol.27, issue.5, pp.1216-1242, 2012.
DOI : 10.1002/ijc.26127

J. Groarke, G. He, Y. Hou, S. Kim, S. Kovats et al., -(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6, J. Med. Chem, issue.422, pp.53-7938, 2010.

B. Marquet, J. C. Morris, J. A. Endicott, B. Joseph, and L. Meijer, Meriolins (3-(Pyrimidin- 4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex, J. Med. Chem, vol.51, issue.4, pp.737-51, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00319787

H. Galons, N. Oumata, and L. Meijer, Cyclin-dependent kinase inhibitors: a survey of recent patent literature, Expert Opinion on Therapeutic Patents, vol.57, issue.4, pp.377-404, 2010.
DOI : 10.1158/0008-5472.CAN-05-1276

F. Rizzolio, T. Tuccinardi, I. Caligiuri, C. Lucchetti, and A. Giordano, CDK Inhibitors: From the Bench to Clinical Trials, Current Drug Targets, vol.11, issue.3, pp.279-90, 2010.
DOI : 10.2174/138945010790711978

P. S. Sharma, R. Sharma, and R. Tyagi, Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr. Cancer Drug Targets, pp.53-75, 2008.

I. Rabinowitz, A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer, Am. J. Clin. Oncol, vol.33, issue.4, pp.393-400, 2010.

J. Kortmansky, D. P. Kelsen, G. K. Schwartz, and E. M. O-'reilly, A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer, Pancreatology, issue.4, pp.9-404, 2009.

M. Hassan, H. Sallam, and Z. Hassan, The Role of Pharmacokinetics and pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor ? Roscovitine, Sultan. Qaboos. Univ. Med. J, vol.11, pp.165-78, 2011.

Y. Zhu, R. Bannerji, and P. Statkevich, Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

M. Mita, A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.29, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.3080

M. A. Pacciarini and E. Calvo, Phase I study of the oral CDK-TRKA inhibitor PHA- 848125 in recurrent malignant glioma (MG), J. Clin. Oncol, vol.28, p.15, 2010.

S. Cresta, C. Sessa, G. Del-conte, A. Locatelli, E. Gallerani et al., Phase l study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration., Journal of Clinical Oncology, vol.28, issue.15_suppl
DOI : 10.1200/jco.2010.28.15_suppl.3065

F. Graf, F. Wuest, and J. Pietzsch, Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging Advances in Cancer Therapy, 2011.

S. Randolph, S. A. Ely, and S. Chen-kiang, A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma, Blood, vol.116, 2010.

D. J. Slamon, S. A. Hurvitz, S. Applebaum, J. A. Glaspy, M. K. Allison et al., Phase I study of PD0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer, J. Clin. Oncol, vol.28, p.15, 2010.

R. S. Finn, J. P. Crown, K. Boer, I. Lang, R. J. Parikh et al., Results of a randomized phase 2 study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in combination with Letrozole vs Letrozole alone for first-line treatment of, HER2-) advanced breast cancer

J. A. Whitlock, M. Krailo, J. M. Reid, S. L. Ruben, M. M. Ames et al., Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study, Journal of Clinical Oncology, vol.23, issue.36
DOI : 10.1200/JCO.2004.01.0660

B. Rovin, C. Kefauver, S. M. Devine, D. M. Lucas, A. Johnson et al., Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias, Haematologica, issue.7, pp.95-1098, 2010.

N. A. Heerema, D. Jarjoura, L. J. Schaaf, J. C. Byrd, M. R. Grever et al., Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia, Blood, issue.12, pp.113-2637, 2009.

T. S. Lin, J. T. Dalton, and D. Wu, Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL), J. Clin. Oncol, issue.14, pp.22-6564, 2004.

. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders, J. Clin. Oncol, vol.28, issue.3, pp.418-441, 2010.

M. Malumbres and M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm, Nature Reviews Cancer, vol.436, issue.3, pp.153-66, 2009.
DOI : 10.1038/nrc2602

G. Schwartz, Treatment of growing teratoma syndrome, N. Engl. J. Med, vol.360, issue.4, pp.423-427, 2009.

M. P. Torva, K. Barnes, C. Barford, ;. T. Benanti, ;. X. Zheng et al., Biaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases. Part I, Bioorganic & Medicinal Chemistry Letters, vol.19, issue.23, pp.6608-6612, 2009.
DOI : 10.1016/j.bmcl.2009.10.025

M. P. Torva, K. Barnes, L. Alicea, ;. T. Benanti, ;. X. Zheng et al., Heterobiaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases. Part II, Bioorganic & Medicinal Chemistry Letters, vol.19, issue.23, pp.6613-6617, 2009.
DOI : 10.1016/j.bmcl.2009.10.011

K. Bettayeb, D. Baunbaek, C. Delehouze, N. Loaëc, A. J. Hole et al., CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells, Genes & Cancer, vol.1, issue.4, pp.369-80, 2010.
DOI : 10.1177/1947601910369817

L. Tang, M. H. Li, P. Cao, F. Wang, W. R. Chang et al., Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives, Journal of Biological Chemistry, vol.280, issue.35, pp.31220-31229, 2005.
DOI : 10.1074/jbc.M500805200

M. Orság, L. Havlícek, and M. Strnad, Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor, Cell. Mol. Life Sci, vol.62, pp.1763-71, 2005.

B. Schutte and D. Vaulot, Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases, Biology of the Cell, vol.83, pp.2-3, 1995.

M. Strnad and V. Kry?tof, A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors, J. Med. Chem, vol.2013, issue.15, pp.56-6234

J. A. Jakubowski, Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists, J. Med. Chem, vol.40, pp.2843-57, 1997.

G. Casiraghi, G. Casnati, M. Cornia, A. Pochini, G. Puglia et al., Selective Reactions using Metal Phenoxides

G. Casiraghi, G. Casnati, G. Puglia, G. Sartori, and G. Terenghi, Selective reactions between phenols and formaldehyde. A novel route to salicylaldehydes, Journal of the Chemical Society, Perkin Transactions 1, pp.1862-65, 1980.
DOI : 10.1039/p19800001862

K. Mori, Y. Ichikawa, M. Kobayashi, T. Akiyama, Y. Shibata et al., Enantioselective Synthesis of Multisubstituted Biaryl Skeleton by Chiral Phosphoric Acid Catalyzed Desymmetrization/Kinetic Resolution Sequence, Journal of the American Chemical Society, vol.135, issue.10
DOI : 10.1021/ja311902f

N. U. Hofslokken, L. Skattebol, T. P. Tuchagues, and M. Ogren, Convenient Method for the ortho-Formylation of Phenols., Acta Chemica Scandinavica, vol.53, pp.258-262, 1999.
DOI : 10.3891/acta.chem.scand.53-0258

J. Y. Goujon, F. Zammattio, J. M. Chrétien, and I. Beaudet, A new approach to 2,2- disubstituted chromenes and tetrahydroquinolines through intramolecular cyclization of chiral 3,4-epoxy alcohols, Tetrahedron, issue.18, pp.60-4037, 2004.

N. Oumata, Y. Ferandin, L. Meijer, and H. Galons, Practical Synthesis of Roscovitine and CR8, Organic Process Research & Development, vol.13, issue.3, pp.643-687, 2009.
DOI : 10.1021/op800284k

J. Benites and A. Rosellón, Mild and rapid method for the generation of o-quinone methide intermediates. Synthesis of puupehedione analogues, Tetrahedron, vol.62, issue.25, pp.6012-6029, 2006.

G. Meyer, Conjugate and Nonconjugate Reduction with LiAlH 4 et NaBH 4, J. Chem

B. Karimi, A. Zamani, and D. Zareyee, N-Iodosuccinimide (NIS) as a mild and highly chemoselective catalyst for deprotection of tert-butyldimethylsilyl ethers, Tetrahedron Letters, vol.45, issue.49, pp.9139-9180, 2004.
DOI : 10.1016/j.tetlet.2004.09.157

K. Hattori, H. Sajiki, and K. Hirota, Undesirable deprotection of O-TBDMS groups by Pd/C-catalyzed hydrogenation and chemoselective hydrogenation using a Pd/C(en) catalyst, Tetrahedron, issue.11, pp.57-2109, 2001.

B. S. Safina, S. Baker, M. Baumgardner, P. M. Blaney, B. K. Chan et al., Discovery of Novel PI3-Kinase ?? Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition, Journal of Medicinal Chemistry, vol.55, issue.12
DOI : 10.1021/jm3003747

J. M. Murray, Z. K. Sweeney, B. K. Chan, M. Balazs, E. Bradley et al., Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta, Journal of Medicinal Chemistry, vol.55, issue.17, pp.7686-95, 2012.
DOI : 10.1021/jm300717c

A. E. Shinkwin, W. J. Whish, and M. D. Threadgill, Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP), Bioorganic & Medicinal Chemistry, vol.7, issue.2, pp.297-308, 1999.
DOI : 10.1016/S0968-0896(98)00210-7

J. M. Barker, P. R. Huddleston, and M. L. Wood, A RAPID CONVERSION OF 3-OXOTHIOLANES INTO 3-AMINOTHIOPHENES, Synthetic Communications, vol.107, issue.16, pp.32-2565, 2002.
DOI : 10.1021/jo01292a012

Y. H. Song and H. Son, Synthesis of new 1-phenylthieno[1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one derivatives, Journal of Heterocyclic Chemistry, vol.58, issue.3, pp.597-603, 2011.
DOI : 10.1002/jhet.549

M. Gutschow and J. C. Powers, A new dimerization reaction producing 2-amino-9- oxopyrrolo-[2,1-b]quinazoline-1-carbonitriles and analogous pyrrolo-[1,2-a]thieno, p.2

M. Zatloukal, M. Gemrotov, K. Dole?al, L. Havli?ek, L. Spíchal et al., Novel potent inhibitors of A. thaliana cytokinin oxidase/dehydrogenase, Bioorganic & Medicinal Chemistry, vol.16, issue.20, pp.16-9268, 2008.
DOI : 10.1016/j.bmc.2008.09.008

H. Bernard, G. Bülow, U. Lange, H. Mack, T. Pfeiffer et al., Technical Scale Synthesis of a New and Highly Potent Thrombin Inhibitor., ChemInform, vol.36, issue.8, pp.2367-75, 2004.
DOI : 10.1002/chin.200508199

E. Cabrera, V. Easwaran, B. De, and G. Zhang, Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3, Bioorg. Med. Chem. Lett, issue.21, pp.16-5633, 2006.

B. Yu, A. Liu, L. He, B. Li, Z. Diao et al., Catalyst-free approach for solvent-dependent selective oxidation of organic sulfides with oxone, Green Chemistry, vol.65, issue.4, pp.957-962
DOI : 10.1039/c2gc00027j

W. Zhu, Y. Liu, X. Zhai, X. Wang, Y. Zhu et al., Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents, European Journal of Medicinal Chemistry, vol.57, pp.162-75, 2012.
DOI : 10.1016/j.ejmech.2012.09.002

T. Yitzhak, S. Del-valle, D. Jaramillo, S. G. Srivatsan, A. Rios et al., Designing new isomorphic fluorescent nucleobase analogues: the thieno, Tetrahedron, vol.3, issue.63, pp.3608-3622, 2007.

V. Smith, F. I. Raynaud, P. Workman, and L. Kelland, Characterisation of a human colorectal cell line with acquired resistance to flavopiridol, Mol. Pharmacol, vol.60, pp.885-893, 2001.

B. A. Averill, M. Kraig, and C. Yagera, Structure-based design, synthesis, and study of pyrazolo